Business
Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.
Calgary, Alberta--(Newsfile Corp. - April 8, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.Calgary, Alberta--(Newsfile Corp. - April 8, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0.F) (\"Hemostemix\" or the \"Company\") is pleased to announce it is trading on the Frankfurt Stock Exchange under symbol 2VF0.F and it has engaged HE Capital Markets Ltd. (HE Capital) to design and implement a North American and European multimedia digital advertising campaign on certain investor-focused and financial market websites. HE Capital will also provide other media communications services to raise the company's overall corporate profile in North America and Europe.Thomas Smeenk, CEO, said: \"With the listing on Frankfurt and the engagement of HE Capital, we are deepening our liquidity pools, introducing Hemostemix to a broader investment community. In the USA we are working to up-list the company, and we are exploring how best to reach our audience in Asia.\" The cash consideration to be paid by the Company for these services consists of USD $18,000 for an initial three-month campaign. HE Capital acts at arm's length to Hemostemix and does not currently have any interest, directly or indirectly, in the company or its securities. HE Capital may choose to acquire securities of Hemostemix in the future.HE Capital is a London-based investor relation and capital markets advisory firm, providing comprehensive communications solutions to public company clients in North America and Europe through a combination of investor relations, public relations, and digital and social media services. HE Capital's office address is 6 Hays Lane, London Bridge, London, SE1 2HB, United Kingdom.About HemostemixHemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. On October 21, 2019, the Company an...